Menu Search
Equities

Demant A/S

DEMANT:CPH

Demant A/S

Actions
Health CareMedical Equipment and Services
  • Price (DKK)258.00
  • Today's Change-1.60 / -0.62%
  • Shares traded272.51k
  • 1 Year change-7.29%
  • Beta1.4002
Data delayed at least 15 minutes, as of Nov 21 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Demant A/S had net income fall -13.78% from 2.08bn to 1.80bn despite a 13.89% increase in revenues from 19.71bn to 22.44bn.
Gross margin75.45%
Net profit margin11.85%
Operating margin19.33%
Return on assets8.52%
Return on equity28.75%
Return on investment11.68%
More ▼

Cash flow in DKKView more

In 2023, Demant A/S did not generate a significant amount of cash. However, the company earned 4.27bn from its operations for a Cash Flow Margin of 19.03%. In addition the company used 1.79bn on investing activities and also paid 2.44bn in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share43.36
Tangible book value per share-23.22
More ▼

Balance sheet in DKKView more

Demant A/S has a Debt to Total Capital ratio of 62.44%, a lower figure than the previous year's 105.90%.
Current ratio1.42
Quick ratio1.06
Total debt/total equity1.68
Total debt/total capital0.6244
More ▼

Growth rates in DKK

Year on year, growth in earnings per share excluding extraordinary items increased 13.67%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)9.34
EPS (TTM) vs
TTM 1 year ago		7.68
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.